Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
A phase 1/2 trial of BG1805 in acute myeloid leukaemia, run by Guangzhou Bio-gene Technology Co., Ltd, now recruiting.
Overview
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT06118788 by Guangzhou Bio-gene Technology Co., Ltd, with 24 participants planned, started 2024-03-07 and due to reach its primary completion in 2027-03. Interventions recorded: BG1805.
Similar pages
not linked directly; found by shared links- TrialMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Study of U32 in Patients With Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Shares Acute myeloid leukaemia and the tag pipeline.